Long-term Treatment of Hypogonadal Men with Testosterone Produces Substantial and Sustained Weight Loss
Overview
Nutritional Sciences
Physiology
Affiliations
Objective: This study analyzed the effects of normalization of serum testosterone (T) levels on anthropometric parameters in hypogonadal men.
Design And Methods: Open-label, single-center, cumulative, prospective registry study of 255 men (aged 33-69 years, mean 58.02 ± 6.30 years), with T levels below 12.13 nmol/L (mean: 9.93±1.38). 215 men for at least 2 years, 182 for 3 years, 148 for 4, and 116 for at least 5 years were studied. They received parenteral T undecanoate 1,000 mg/12 weeks after an initial interval of 6 weeks.
Results: Body weight (BW) decreased from 106.22 ± 16.93 kg to 90.07 ± 9.51 kg. Waist circumference (WC) reduced from 107.24 ± 9.14 cm to 98.46 ± 7.39 cm. BMI (m/kg(2) ) declined from 33.9 ± 5.51 m/kg(2) to 29.13 ± 3.09 m/kg(2) . All parameters examined were statistically significant with P < 0.0001 versus baseline and versus the previous year over 5 years indicating a continuous weight loss over the full observation period. The mean per cent weight loss after 1 year was 4.16 ± 0.31%, after 2 years 7.54 ± 0.32%, after 3 years 9.23 ± 0.33%, after 4 years 11.42 ± 0.35% and after 5 years 13.57 ± 0.37%.
Conclusions: In an uncontrolled, observational cohort, normalizing serum T to normal physiological levels produced consistent loss of BW, WC, and BMI. These improvements were progressive over the full 5 years of the study.
Chen B, Tsai P, Jiann B Sex Med. 2025; 12(6):qfae089.
PMID: 39801930 PMC: 11723798. DOI: 10.1093/sexmed/qfae089.
Mlynarz N, Miedziaszczyk M, Wieckowska B, Szalek E, Lacka K Int J Mol Sci. 2024; 25(22).
PMID: 39596286 PMC: 11594927. DOI: 10.3390/ijms252212221.
Management of male obesity-related secondary hypogonadism: A clinical update.
Shenoy M, Mondal S, Fernandez C, Pappachan J World J Exp Med. 2024; 14(2):93689.
PMID: 38948417 PMC: 11212738. DOI: 10.5493/wjem.v14.i2.93689.
Hackett G, Kirby M, Rees R, Jones T, Muneer A, Livingston M World J Mens Health. 2023; 41(3):508-537.
PMID: 36876744 PMC: 10307648. DOI: 10.5534/wjmh.221027.
Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity.
Yazici D, Eser H, Kiyici S, Sancak S, Sezer H, Uygur M Obes Facts. 2022; 16(2):149-163.
PMID: 36349778 PMC: 10028372. DOI: 10.1159/000526808.